These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 37368200)
61. Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapse. Lal A; Kwan E; al Mahr M; Zhou L; Ferrara D; Tobias V; O'Gorman Hughes D; Haber M; Norris MD; Marshall GM Mol Pathol; 1998 Oct; 51(5):277-81. PubMed ID: 10193523 [TBL] [Abstract][Full Text] [Related]
62. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029 [TBL] [Abstract][Full Text] [Related]
63. Microfluidic Affinity Selection of B-Lineage Cells from Peripheral Blood for Minimal Residual Disease Monitoring in Pediatric B-Type Acute Lymphoblastic Leukemia Patients. Witek MA; Larkey NE; Bartakova A; Hupert ML; Mog S; Cronin JK; Vun J; August KJ; Soper SA Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39408948 [TBL] [Abstract][Full Text] [Related]
64. Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye. Li AH; Forestier E; Rosenquist R; Roos G Exp Hematol; 2002 Oct; 30(10):1170-7. PubMed ID: 12384148 [TBL] [Abstract][Full Text] [Related]
65. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia]. Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185 [TBL] [Abstract][Full Text] [Related]
66. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study. Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260 [TBL] [Abstract][Full Text] [Related]
67. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. Ouyang J; Goswami M; Peng J; Zuo Z; Daver N; Borthakur G; Tang G; Medeiros LJ; Jorgensen JL; Ravandi F; Wang SA Am J Clin Pathol; 2016 Jun; 145(6):769-77. PubMed ID: 27298396 [TBL] [Abstract][Full Text] [Related]
68. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891 [TBL] [Abstract][Full Text] [Related]
69. Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia. Ding Y; Liu Z; Wang H; Xiong S; Zhai Z Scand J Clin Lab Invest; 2023 Sep; 83(5):340-347. PubMed ID: 37355341 [TBL] [Abstract][Full Text] [Related]
70. Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission. Klyuchnikov E; Badbaran A; Massoud R; Fritzsche-Friedland U; Freiberger P; Ayuk F; Wolschke C; Bacher U; Kröger N Transplant Cell Ther; 2022 Jul; 28(7):374.e1-374.e9. PubMed ID: 35429661 [TBL] [Abstract][Full Text] [Related]
71. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]. zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545 [TBL] [Abstract][Full Text] [Related]
72. Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis. Health Quality Ontario Ont Health Technol Assess Ser; 2016; 16(8):1-83. PubMed ID: 27099644 [TBL] [Abstract][Full Text] [Related]
73. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Campana D Hematol Oncol Clin North Am; 2009 Oct; 23(5):1083-98, vii. PubMed ID: 19825454 [TBL] [Abstract][Full Text] [Related]
74. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119 [TBL] [Abstract][Full Text] [Related]
75. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791 [TBL] [Abstract][Full Text] [Related]
76. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Denys B; van der Sluijs-Gelling AJ; Homburg C; van der Schoot CE; de Haas V; Philippé J; Pieters R; van Dongen JJ; van der Velden VH Leukemia; 2013 Mar; 27(3):635-41. PubMed ID: 22945774 [TBL] [Abstract][Full Text] [Related]
77. Assessment of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: A Multicenter Study From Turkey. Tüfekçi Ö; Evim MS; Güneş AM; Celkan T; Karapinar DY; Kaya Z; Baysal B; Baytan B; Koçak Ü; Yilmaz Ş; Çinar S; Ören H J Pediatr Hematol Oncol; 2022 Mar; 44(2):e396-e402. PubMed ID: 35129146 [TBL] [Abstract][Full Text] [Related]
78. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL). Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424 [TBL] [Abstract][Full Text] [Related]
79. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. Lovisa F; Zecca M; Rossi B; Campeggio M; Magrin E; Giarin E; Buldini B; Songia S; Cazzaniga G; Mina T; Acquafredda G; Quarello P; Locatelli F; Fagioli F; Basso G Br J Haematol; 2018 Mar; 180(5):680-693. PubMed ID: 29359790 [TBL] [Abstract][Full Text] [Related]
80. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ; Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]